Kineret (anakinra) is a protein pharmaceutical. Anakinra was first approved as Kineret on 2001-11-14. It is used to treat cryopyrin-associated periodic syndromes and rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against interleukin-1 receptor type 1.
|Indication||cryopyrin-associated periodic syndromes, rheumatoid arthritis|
|Drug Class||Interleukin-1 (IL-1) receptor antagonists|